Canaccord Genuity Maintains a 'Buy' on Watson Pharmaceuticals (WPI); CBRX Management Meeting - More Support for WPI and PROCHIEVE Upside
Tweet
Share
E-mailGet Alerts WPI Hot Sheet
Price: $85.73 --0%
Rating Summary:
13 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
13 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on Watson Pharmaceuticals (NYSE: WPI) price target of $85.00.
Canaccord analyst, Randall Stanicky, said, "We met with management of Columbia Laboratories (Nasdaq: CBRX)(Not rated) on Friday and leave with continued confidence in our above-consensus forecasts for PROCHIEVE, which if approved will be Watson’s first on market treatment for women at risk of pre-term birth. We have detailed what we believe are the most relevant details from our meeting, with emphasis around understanding potential ACOG guidelines and drivers of market size. While it is hard to argue that BUY-rated WPI isn’t well owned, we believe that the PROCHIEVE opportunity is under-appreciated and has potential to be a meaningful P&L driver with updates coming near-term ahead of the Feb. 26 PDUFA."
For more ratings news on Watson Pharmaceuticals click here and for the rating history of Watson Pharmaceuticals click here.
Shares of Watson Pharmaceuticals closed at $69.15 yesterday.
Canaccord analyst, Randall Stanicky, said, "We met with management of Columbia Laboratories (Nasdaq: CBRX)(Not rated) on Friday and leave with continued confidence in our above-consensus forecasts for PROCHIEVE, which if approved will be Watson’s first on market treatment for women at risk of pre-term birth. We have detailed what we believe are the most relevant details from our meeting, with emphasis around understanding potential ACOG guidelines and drivers of market size. While it is hard to argue that BUY-rated WPI isn’t well owned, we believe that the PROCHIEVE opportunity is under-appreciated and has potential to be a meaningful P&L driver with updates coming near-term ahead of the Feb. 26 PDUFA."
For more ratings news on Watson Pharmaceuticals click here and for the rating history of Watson Pharmaceuticals click here.
Shares of Watson Pharmaceuticals closed at $69.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- New Street Research Upgrades Micron Technology (MU) to Buy
- DA Davidson Reiterates Neutral Rating on Timken (TKR)
- Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
